Amolyt Pharma Announces $138 Million Series C Financing Led By Sofinnova Partners And Co-Led By Intermediate Capital Group
Amount Raised
$138 Million
Round Type
Series C
LyonBiotechnologyHealth CareMedicalDescription
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced the closing of a €130 million (approx. $138M) Series C equity financing. The financing was led by Sofinnova Partners and co-led by Intermediate Capital Group (ICG). Cédric Moreau, partner at Sofinnova Partners and Toby Sykes, managing director at ICG, will join Amolyt’s Board of Directors
Who else raised in Medical and Biotechnology around the same time
Companies in the same sectors as Amolyt Pharma that raised within 45 days of this round, from Fundz verified event records.
- U.S. Renal Care raised $3.1M (Seed) on February 16, 2023.
- Previa Medical raised $2.2M (Seed) on February 16, 2023.
- Rhaeos raised $11M (Series A) on February 16, 2023.
- Rhaeos raised $6.2M on February 15, 2023.
- Predicta Med raised an undisclosed amount (Funding Round) on February 10, 2023.
- NeOnc Technologies raised $10M on February 8, 2023.
Who to call at Amolyt Pharma, and when
A new round usually means Amolyt Pharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Amolyt Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Amolyt Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Amolyt Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Amolyt Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Amolyt Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.